Trial Profile
An Imaging and Histopathologic Study to Predict Response to Sunitinib Therapy in Patients With Metastatic or Locally Advanced Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacogenomic; Therapeutic Use
- 21 Jun 2019 Status changed from active, no longer recruiting to completed.
- 21 Jun 2019 Status changed from active, no longer recruiting to completed.
- 14 Dec 2015 Status changed from completed to active, no longer recruiting, as reported by ClinicalTrials.gov (NCT01026337).